The PARP1 inhibitor olaparib combines well with DNA damaging treatments and other chemotherapies [30, 31] and shows combination effects with selinexor in triple negative breast cancers cells independent of BRCA1 status [32]. Here, BRCA1 is linked to triple-negative breast carcinoma.